Ext. 2021
Jorge Alegre-Cebollada

We are a multidisciplinary team of scientists who investigate how mechanical forces determine muscle function at the molecular, cellular, tissue and organismal levels. Our motivation is to improve the understanding, diagnosis and treatment of cardiovascular and musculoskeletal diseases. At the same time, we train scientists, awake vocations in science and contribute to strengthen and disseminate the scientific culture.

Ext. 1502
Vicente Andrés García

Cardiovascular disease (CVD) is the main health and socio-economic problem worldwide, in part due to the progressive aging that the world population is experiencing. Atherosclerosis and heart failure contribute significantly to CVD-related morbimortality in the elderly.

Ext. 3115
Rui Benedito

The laboratory’s main objective is to obtain a better understanding of how distinct signalling pathways control the different context-dependent behaviours of the diverse cell types that compose the vascular system and that are essential for new blood vessel formation.

Ext. 2012
Jacob Fog Bentzon

Our research group investigates the mechanisms by which atherosclerosis forms.

Ext. 4110
Héctor José Bueno Zamora

The Multidisciplinary Translational Research (MTCR) Group of CNIC is a platform for innovative knowledge generation in health and disease.

Ext. 3110
José Luis de la Pompa Mínguez

We study the role of signaling pathways in cardiovascular development with the goal of identifying disease mechanisms and biomarkers.

Ext. 1158
Miguel Ángel del Pozo Barriuso

The interplay of cells and tissues with mechanical forces from their environment emerges as a novel key aspect of both organismal homeostasis and disease.

Ext. 2309
José Antonio Enríquez Domínguez

Our research activity has focused on the study of mammalian mitochondrial electron transport chain (MtETC) and H+ -ATP synthase, which constitute the oxidative phosphorylation system (OxPhos).

Ext. 2022
Rodrigo Fernández Jiménez

Our group focuses on cardiovascular disease prevention and health promotion. We work on multidisciplinary programs in close collaboration with schools and communities, targeting both children and adults.

Ext. 1510
David Filgueiras Rama

The Advanced Development in Arrhythmia Mechanisms and Therapy (ADAM-T) laboratory focuses on investigating from a multidisciplinary approach, the mechanisms underlying cardiac arrhythmias that occur in highly prevalent cardiovascular diseases in the general population, as well as in specific subsets at particular risk of sudden cardiac death.

Ext. 4280
Valentín Fuster Carulla

Our group has developed research applications for noninvasive, high-resolution and high-sensitivity imaging technologies to support translational research and population studies in preclinical atherosclerosis.

Ext. 4304
José Javier Fuster Ortuño

Our laboratory investigates the interplay between the hematopoietic and the cardiovascular systems in the context of cardiovascular disease, with a particular focus on the pathophysiology of atherosclerosis, the underlying cause of most heart attacks and strokes.

Ext. 70265
Ana García Álvarez

Our laboratory focuses on the study of myocardial diseases leading to heart failure (HF) and pulmonary hypertension (PH) from a translational perspective ranging from molecular studies and experimental models to multicenter clinical trials.

Ext. 70136
Inés García Lunar

Our approach focuses on the use of imaging modalities to study cardiovascular health and transition to subclinical damage and stablished cardiovascular disease.

Ext. 4101
Pablo Garcia-Pavia

Our group focuses on investigating from a multidisciplinary approach, the implication of genetics in cardiomyopathies. We perform translational research from humans to mice and look to improve how patients are diagnosed and treated.

Ext. 1504
Andrés Hidalgo Alonso

Our laboratory is interested in the biology of inflammation and immune cells.

Ext. 4302
Borja Ibáñez Cabeza

Our laboratory focuses on the study of myocardial diseases, ranging from ischemia/reperfusion to heart failure, including that associated with cancer therapy-induced cardiotoxicity.

Ext. 1512
José Jalife Sacal

The general focus of Dr. Jalife's laboratory is the understanding of the cellular and molecular mechanisms of arrhythmias and sudden cardiac death (SCD).

Ext. 3309
Enrique Lara Pezzi

Our lab studies the molecular mechanisms that regulate the development of heart failure.

Ext. 2009
Pilar Martin

Our group seeks to study the therapeutic and diagnostic potential of T cells, their immunomodulatory receptors and microRNAs, in the management of cardiovascular disease (CVD) and in the development of precision medicine tools.

Ext. 3117
Nadia Mercader

The epicardium is a unicellular epithelial layer of that envelops the myocardium. It derives from the proepicardium (PE), a group of cells that arises at the inflow tract of the forming heart. PE cells attach to the myocardium and form an epithelial covering, called the epicardium.

Ext. 3312
María Ángeles Moro Sánchez

The interest of our group is cerebrovascular disease, one of the leading causes of death and disability, with an increasing prevalence due to the ageing of the population.

Ext. 70297
Pura Muñoz Cánoves

Our group aims to understand the cellular and molecular mechanisms regulating striated muscle regeneration and growth in physiology and pathology, as well as in aging.

Ext. 4107
Carlos Perez Medina

Formulation of drugs into nanoparticles can potentially improve their pharmacokinetics, stability and toxicity profile, thereby augmenting their therapeutic index. In addition, nanomedicines can be designed to selectively deliver their cargo to a specific tissue or cell population.

Ext. 4120
Silvia Priori

Sudden cardiac death (SCD) is a leading cause of death in western countries: coronary artery disease is the major cause of SCD in older subjects while inherited arrhythmogenic diseases are the leading cause of SCD in younger individuals.

Ext. 2020
Almudena Ramiro

We are interested in various aspects of B cell biology and the antibody immune response, in particular in the context of atherosclerosis and cardiovascular disease.

Ext. 1150
Juan Miguel Redondo Moya

Our group is interested in the molecular mechanisms regulating vascular and cardiac remodeling, including that mediated by genes regulated by Angiotensin-II (AngII) and calcineurin (CN).

Ext. 3306
María Mercedes Ricote Pacheco

Our group investigates the transcriptional and epigenetic control of immune and cardiovascular cells in homeostasis and disease, with a particular focus on the molecular mechanisms underlying the actions of nuclear receptors.

Ext. 2004
Guadalupe Sabio Buzo

Our recently formed group investigates the involvement of SAPKs in the development of cancer and atherosclerosis induced by obesity.

Ext. 3112
Hesham Sadek

The Myocardial regeneration via cardiomyocyte cell cycle regulation lab joined the CNIC in November 2022.

Ext. 2000
Francisco Sánchez Madrid

Intercellular communication is fundamental to the innate and adaptive immune responses.

Ext. 2010
David Sancho Madrid

Our current research is focused on the function of dendritic cells (DCs) and macrophages as key immune sentinels that initiate and modulate immunity, inflammation and tolerance. Manipulation of these cells holds promise as a potent immunotherapy tool for many diseases with an immune component, including infectious diseases, autoimmune diseases, cardiovascular diseases (CVD) and cancer.

Ext. 3100
Miguel Torres

We are interested in understanding the cellular basis of developmental processes and how this is controlled by transcription factor networks (TFN). We have developed genetic methods in the mouse that allow us to trace cell lineages using clonal analysis or functional mosaics.

Ext. 70203
Jesús María Vázquez Cobos

Our group works on the development of high-throughput quantitative approaches for the dynamic analysis of the deep proteome, which are being applied to basic and translational projects in the cardiovascular field.

Ext. 4310
Florian Anton Weinberger

Our group is interested in developing novel regenerative therapies for heart failure